Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.00    0.20 (0.20%)
Bid:
102.40
Ask:
102.80
Spread: 0.40 (0.391%)
Market Cap: £167.22m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q1 Trading update

27 Apr 2017 07:00

RNS Number : 4734D
Synthomer PLC
27 April 2017
 

April 27th 2017

Synthomer plc

Q1 Trading update

Progress in Q1, in line with expectations; 2017 outlook reaffirmed

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the first quarter ended March 31st, 2017.

Trading

Europe and North America

The Europe and North America segment delivered a solid performance with results ahead of Q1 2016 reflecting the acquisitions of both PAC and Perstorp Oxo Belgium, and robust trading in the heritage business. Substantially higher volumes predominantly reflected the positive impact of PAC following its full integration into the business. Unit margins were also up on 2016, in line with expectations. Whilst raw material prices have been volatile, we continued to effectively manage these movements and remain confident of being able to do so going forward.

Asia and Rest of World

Overall performance of the Asia and Rest of World segment was in line with our expectations. Nitrile margins remained stable relative to Q4 2016, albeit lower than the strong comparative Q1 2016 as expected. Volumes were lower than the comparative period reflecting the sale of our South African business in August 2016, and some short term destocking in March following continued raw material price volatility. The underlying trends remain unchanged from our 2016 FY results in March.

Financial Position

Net debt increased from £150 million at the year end to £257m at 31 March 2017. This was due to the acquisition of Perstorp Oxo Belgium for €78m (£65m) in March with the balance accounted for by working capital in a volatile but net rising raw material price environment.

2017 outlook reaffirmed

Overall, the Group continues to trade in line with the Board's expectations, and accordingly the view for Full Year 2017 remains unchanged.

-ENDS-

 

 

 

 

Enquiries:

Calum MacLean, Chief Executive Officer +44 1279 436 211

Stephen Bennett, Chief Financial Officer

Charles Armitstead, Teneo Blue Rubicon +44 203 603 5220

 

The Company will hold a conference call for investors and analysts at 0800 BST today. 

Please dial + 44 808 237 0030 entering conference ID: 70430346# to gain access to the call.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIFMPTMBBTBPR
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.